entertainment -WSS

entertainment

author：focus 2025-08-12 06:44:12 - browse：71113

Photograph of a person wearing blue gloves counts money. -- health business coverage from STAT — Adobe

WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another.

Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures. But in Medicare, boosting payments in one area almost always means cutting them somewhere else. So to pay for that, doctors across the country will see a roughly 3% cut to a factor that determines how much Medicare pays them for caring for seniors.

The change has pitted certain specialties against primary care doctors. A host of surgeons’ groups, including the American College of Surgeons, plainly criticized family physicians in a recent letter to Medicare, saying there’s no “valid justification” for the boost and calling it an “inappropriate” overpayment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： New weight loss drugs work. But how can they best be used?

hotspot

WSS

Can sheer will power keep patients alive in their dying hours?

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Federal weight loss drug coverage is 30 years out of date

Federal weight loss drug coverage is 30 years out of date

The biotech scorecard for Q1: 17 stock

Carvykti CAR

focus

entertainment

leisure time

What does generative AI mean for health care? We asked experts

Three trends to watch in biotech in 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

White House finalizes ITC's import ban of latest Apple Watches

Medical leaders decry Supreme Court decision on affirmative action

GSK Flovent asthma inhalers replaced by authorized generics

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The FDA must approve intranasal treatments for anaphylaxis

The high cost of giving birth even with insurance

Ahead of JPM, here's who's profiting most in health care

hotspot

David Ricks of Eli Lilly: best biopharma CEO of 2023

J&J to buy cancer drug developer Ambrx Biopharma

3 trends to watch in health tech's hiring outlook for 2024

White House finalizes ITC's import ban of latest Apple Watches

Medicare drug price negotiation hasn't dried up venture capital

Feng Zhang CRISPR delivery startup lays off quarter of staff

hotspot

focus

hotspot

entertainment